{
  "docId": "019de071-473e-712d-87f0-b99471a2308d",
  "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea",
  "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7827299,
  "pageNumber": 30,
  "pageCount": 40,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "Includes a table of IC50 values and two line charts showing tumor volume reduction in CDX models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/30",
  "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d",
  "deckJsonHref": "/decks/019de071-473e-712d-87f0-b99471a2308d.json",
  "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.4,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Tumor volume reduction in Ba/F3 EML4-ALK v1 G1202R/L1196M CDX models for NVL-655 vs vehicle.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "629c0679-ed86-439c-a155-9512da8a93dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.75,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Tumor volume reduction in Ba/F3 EML4-ALK v1 G1202R/L1196M CDX models for Lorlatinib vs vehicle.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe6b5fc2-48c5-4417-9ea9-ecc37801d3e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.22,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Clinically Relevant Drug-Resistant Mutations, in vitro and in vivo ALK fusion NSCLC models",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3068c66b-6041-4762-8ffe-6d2c7d412aa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.22,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Pelish, H.E., Tangpeerachaikul, A., Kohl, N.E., Shair, M.D., Porter, J.R., and Horan, J.C. AACR Conference 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1108096c-fe0a-4300-b2cc-d0e346e91f61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.7,
        "x": 0.225,
        "y": 0.25
      },
      "kind": "table",
      "text": "IC50 cell viability assay (nM) table comparing NVL-655 to Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib across 4 mutations.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35c57b90-fbb3-4d21-8e96-7a94c31fa089",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.22,
        "y": 0.08
      },
      "kind": "title",
      "text": "Preclinical NVL-655 activity against ALK",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3d5149a-d9c7-4848-843b-62f2b6f219ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "7aa7fb33-4744-4266-9c4a-7fc3361248aa",
      "evidence": "table/data: IC50 cell viability assay (nM) table comparing NVL-655 to Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib across 4 mutations.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}